Liying Zhang

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:301-7. 2008
  2. pmc A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Mol Diagn 11:176-81. 2009
  3. pmc NF-kappaB regulates androgen receptor expression and prostate cancer growth
    Liying Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA
    Am J Pathol 175:489-99. 2009
  4. doi request reprint BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
  5. doi request reprint cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mutat Res 663:84-9. 2009
  6. pmc Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:131-8. 2013
  7. pmc Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Jeff Holzbeierlein
    Department of Urology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 164:217-27. 2004
  8. doi request reprint Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
  9. pmc Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies
    Joseph Vijai
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Genet 9:e1003220. 2013
  10. doi request reprint Expression of androgen receptor and its phosphorylated forms in breast cancer progression
    Qinghu Ren
    Department of Pathology, New York University School of Medicine, New York, New York, USA
    Cancer 119:2532-40. 2013

Collaborators

Detail Information

Publications11

  1. pmc Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:301-7. 2008
    ..MSI has been used and will continue to prevail as the primary screening tool for identifying HNPCC patients...
  2. pmc A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Mol Diagn 11:176-81. 2009
    ..We show that pyrosequencing is a rapid and reliable method that serves as an excellent platform for BRCA founder mutation analysis, especially when only paraffin-embedded tissues are available...
  3. pmc NF-kappaB regulates androgen receptor expression and prostate cancer growth
    Liying Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA
    Am J Pathol 175:489-99. 2009
    ..In addition, levels of both NF-kappaB and AR were strongly correlated in human prostate cancer. Our data suggest that NF-kappaB can regulate AR expression in prostate cancer and that NF-kappaB inhibitors may have therapeutic potential...
  4. doi request reprint BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
    ..Analysis of a tumor specimen indicates loss of heterozygosity. These results support the conclusion that BRCA1 331G > A (R71K) is a deleterious mutation...
  5. doi request reprint cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mutat Res 663:84-9. 2009
    ..These results support the conclusion that BRCA2 IVS4-12del5 is a deleterious mutation. This study will shed light on the reclassification of intronic variants that do not disrupt the 5' and 3' splice sites (the GU-AG rule)...
  6. pmc Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:131-8. 2013
    ....
  7. pmc Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Jeff Holzbeierlein
    Department of Urology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 164:217-27. 2004
    ..The specific pathways of reactivation provide opportunities for classification of resistant tumors and targeted therapies...
  8. doi request reprint Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
    ..Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown...
  9. pmc Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies
    Joseph Vijai
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Genet 9:e1003220. 2013
    ..These results, showing novel susceptibility regions and allelic heterogeneity, point to the existence of pathways of susceptibility to both shared as well as specific subtypes of lymphoid malignancy...
  10. doi request reprint Expression of androgen receptor and its phosphorylated forms in breast cancer progression
    Qinghu Ren
    Department of Pathology, New York University School of Medicine, New York, New York, USA
    Cancer 119:2532-40. 2013
    ..We examined the expression pattern of AR and its phosphorylated forms, Ser-213 (AR-Ser[P]-213) and Ser-650 (AR-Ser[P]-650), in breast cancer and evaluated their association with clinicopathological parameters...
  11. doi request reprint Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...